FI Mulder, M Candeloro, PW Kamphuisen… - …, 2019 - ncbi.nlm.nih.gov
We aimed to evaluate the performance of the Khorana score in predicting venous thromboembolic events in ambulatory cancer patients. Embase and MEDLINE were …
A Chaudhury, A Balakrishnan, C Thai, B Holmstrom… - 2016 - ashpublications.org
BACKGROUND: Venous thromboembolism is a well-known complication of malignancy. The Khorana Risk Score (KRS) utilizes the type of cancer, blood counts, and body mass …
Introduction: Although venous thromboembolism (VTE) is a well-known complication of cancer, predicting and mitigating the risks associated with VTE related to cancer remain a …
Background The Khorana risk score (KRS) for prognosis of venous thromboembolism (VTE) has been rarely explored in Hispanic populations. Objective To determine the value of the …
N van Es, M Ventresca, M Di Nisio… - … of Thrombosis and …, 2020 - Wiley Online Library
Background Oncology guidelines suggest using the Khorana score to select ambulatory cancer patients receiving chemotherapy for primary venous thromboembolism (VTE) …
Background: Guidelines suggest the use of the Khorana score to select patients with solid cancer receiving chemotherapy for thromboprophylaxis to prevent venous thromboembolism …
The Khorana score is recommended for guiding primary venous thromboembolism (VTE) prophylaxis in cancer patients, but its clinical utility overall and across cancer types remains …
F Akasaka-Kihara, D Sueta, M Ishii, Y Maki, K Hirakawa… - JACC: Asia, 2021 - jacc.org
Abstract Background Although the Khorana venous thromboembolism (VTE) risk score (KRS) is well recognized as a simple VTE risk assessment method in patients with cancer …
A Parker, E Peterson, AYY Lee, C de Wit… - Journal of Thrombosis …, 2018 - Elsevier
Essentials• The Khorana score is validated for risk of venous thromboembolism (VTE) in cancer outpatients.• We conducted a multicenter analysis of medically hospitalized cancer …